T1 Disease 2053 2076 hand–foot skin reaction
T2 Disease 2110 2117 fatigue
T3 Biomarker 251 260 sorafenib
T4 Condition 1698 1709 regorafenib
T5 Biomarker 812 825 α-fetoprotein
T6 Condition 2888 2899 regorafenib
T7 Biomarker 2791 2801 third-line
T8 Organism 2504 2512 patients
T9 Biomarker 407 416 sorafenib
T10 Condition 1358 1369 regorafenib
T11 Protein 87 90 HCC
T12 Organism 2122 2130 patients
T13 Protein 979 985 funder
T14 Biomarker 2682 2691 sorafenib
T15 Condition 2748 2759 regorafenib
T16 Condition 1787 1798 regorafenib
T17 Condition 866 877 regorafenib
T18 Condition 1467 1478 regorafenib
T19 Biomarker 2874 2883 sorafenib
T20 Protein 2654 2657 HCC
T21 Disease 1951 1963 hypertension
T22 Organism 2178 2186 patients
T23 Organism 2144 2152 patients
T24 Organism 2081 2089 patients
T25 Organism 545 557 Participants
T26 Disease 2523 2538 hepatic failure
T27 Biomarker 483 492 sorafenib
T28 Condition 2437 2448 regorafenib
T29 Condition 1990 2001 regorafenib
T30 Intervention 762 775 macrovascular
T31 Organism 47 55 patients
T32 Condition 191 202 regorafenib
T33 Condition 2308 2319 regorafenib
T34 Biomarker 418 422 ≥400
T35 Protein 1221 1232 NCT01774344
T36 Intervention 786 798 extrahepatic
T37 Protein 389 392 HCC
T38 Organism 206 214 patients
T39 Organism 2016 2024 patients
T40 Intervention 861 865 oral
T42 Organism 1285 1293 patients
T43 Organism 2817 2825 patients
T44 Biomarker 502 520 Child-Pugh A liver
T45 Organism 1968 1976 patients
T46 Organism 2654 2666 HCC patients
T47 Organism 961 969 patients
T48 Organism 2198 2206 patients
T49 Condition 61 85 hepatocellular carcinoma
T50 Protein 220 223 HCC
T51 Organism 2281 2289 patients
T52 Condition 2164 2173 diarrhoea
T53 Biomarker 124 133 sorafenib
